Portage already owned adjacent parcels to the north and south of the property, and holds an easement along the western edge ...

Healthcare & Pharmaceuticalscategory· March 11, 2025 Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results Pfizer and Arvinas' experimental treatment failed to delay ...

Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug regulator at the Food and Drug Administration, as its new chief medical officer is one of the dumbest, most damaging corporate ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

Viewers reacted positively to the ad’s focus on corporate responsibility and philanthropy. Pfizer’s ad, which aired during the first quarter, aimed to inspire viewers in the fight against cancer.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... 3% GDP growth, and solid corporate balance sheets. He said that despite short-term market turbulence, recession risks ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report). The company’s shares closed ...

and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...